Total Payments
$4,652
2024 Payments
$543.63
Companies
44
Transactions
123
Medicare Patients
30,445
Medicare Billing
$9.5M
Payment Breakdown by Category
Food & Beverage$2,405 (51.7%)
Research$1,844 (39.6%)
Education$402.84 (8.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,405 | 96 | 51.7% |
| Unspecified | $1,844 | 3 | 39.6% |
| Education | $402.84 | 24 | 8.7% |
Payments by Type
General
$2,808
120 transactions
Research
$1,844
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $1,844 | 3 | $0 (2018) |
| Daiichi Sankyo Inc. | $244.50 | 9 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $225.45 | 7 | $0 (2024) |
| PFIZER INC. | $210.53 | 13 | $0 (2024) |
| Exelixis Inc. | $191.99 | 12 | $0 (2018) |
| Gilead Sciences, Inc. | $174.26 | 4 | $0 (2023) |
| Allergan, Inc. | $166.27 | 7 | $0 (2021) |
| Pharmacyclics LLC, an AbbVie Company | $125.83 | 2 | $0 (2022) |
| Seagen Inc. | $117.01 | 6 | $0 (2023) |
| TESARO, Inc. | $103.15 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $543.63 | 28 | Daiichi Sankyo Inc. ($81.43) |
| 2023 | $345.77 | 18 | PFIZER INC. ($79.02) |
| 2022 | $308.28 | 14 | Pharmacyclics LLC, an AbbVie Company ($105.00) |
| 2021 | $380.83 | 16 | Daiichi Sankyo Inc. ($123.73) |
| 2020 | $309.89 | 15 | Allergan, Inc. ($100.46) |
| 2019 | $307.85 | 6 | Gilead Sciences, Inc. ($124.87) |
| 2018 | $1,738 | 9 | Eli Lilly and Company ($1,588) |
| 2017 | $718.40 | 17 | Eli Lilly and Company ($256.66) |
All Payment Transactions
123 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Geron Corporation | RYTELO (Drug) | Food and Beverage | In-kind items and services | $14.96 | General |
| Category: MYELODYSPLASTIC SYNDROME | ||||||
| 12/18/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $17.83 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $13.14 | General |
| Category: Oncology | ||||||
| 11/21/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $16.64 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $19.34 | General |
| Category: Oncology | ||||||
| 10/31/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $19.03 | General |
| Category: ONCOLOGY | ||||||
| 09/25/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $28.96 | General |
| Category: Oncology | ||||||
| 09/10/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $20.58 | General |
| Category: Oncology | ||||||
| 08/20/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $17.94 | General |
| 08/08/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $14.50 | General |
| Category: ONCOLOGY | ||||||
| 07/31/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug), Tazverik | Education | In-kind items and services | $16.23 | General |
| Category: Oncology | ||||||
| 07/30/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $21.92 | General |
| 07/09/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $13.36 | General |
| Category: ONCOLOGY | ||||||
| 06/20/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $13.42 | General |
| Category: ONCOLOGY | ||||||
| 06/18/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $23.22 | General |
| Category: Oncology | ||||||
| 05/21/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $19.37 | General |
| Category: Genetically Defined Disease | ||||||
| 05/10/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $18.27 | General |
| 05/07/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $21.23 | General |
| Category: Rare Disease | ||||||
| 05/06/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $22.32 | General |
| Category: ONCOLOGY | ||||||
| 04/23/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug), Tazverik | Education | In-kind items and services | $16.23 | General |
| Category: Oncology | ||||||
| 04/23/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $15.62 | General |
| Category: ONCOLOGY | ||||||
| 04/19/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $20.23 | General |
| Category: Oncology | ||||||
| 04/19/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $18.94 | General |
| Category: Oncology | ||||||
| 03/12/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $33.16 | General |
| Category: Oncology | ||||||
| 02/14/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $22.52 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 1B OPEN-LABEL - PHASE 2 RANDOMIZED, DOUBLE-BLINDED STUDY EVALUATING GEMCITABINE AND DOCETAXEL WITH OR WITHOUT OLARATUMAB IN THE TREATMENT OF ADVANCED SOFT TISSUE SARCOMA | Eli Lilly and Company | $1,844 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 88 | 7,146 | 173,646 | $7.8M | $2.2M |
| 2022 | 90 | 7,037 | 152,975 | $7.5M | $2.1M |
| 2021 | 97 | 8,089 | 172,365 | $8.4M | $2.6M |
| 2020 | 99 | 8,173 | 192,204 | $8.2M | $2.5M |
Total Patients
30,445
Total Services
691,190
Medicare Billing
$9.5M
Procedure Codes
374
All Medicare Procedures & Services
374 procedure records from CMS Medicare Utilization — Page 1 of 15
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 34 | 12,000 | $1.4M | $514,846 | 37.6% |
| J9299 | Injection, nivolumab, 1 mg | Office | 2023 | 30 | 14,860 | $951,040 | $351,672 | 37.0% |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2023 | 22 | 6,300 | $693,000 | $239,245 | 34.5% |
| J1930 | Injection, lanreotide, 1 mg | Office | 2023 | 20 | 5,400 | $669,600 | $179,659 | 26.8% |
| J9022 | Injection, atezolizumab, 10 mg | Office | 2023 | 12 | 2,136 | $405,840 | $132,628 | 32.7% |
| J1449 | Injection, eflapegrastim-xnst, 0.1 mg | Office | 2023 | 23 | 3,564 | $313,632 | $89,577 | 28.6% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 54 | 70 | $285,880 | $71,123 | 24.9% |
| J1627 | Injection, granisetron, extended-release, 0.1 mg | Office | 2023 | 81 | 11,000 | $132,000 | $50,714 | 38.4% |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 2023 | 15 | 1,320 | $132,000 | $47,500 | 36.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 316 | 507 | $152,100 | $46,188 | 30.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 326 | 615 | $105,165 | $37,075 | 35.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 109 | 395 | $99,935 | $34,829 | 34.9% |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | Office | 2023 | 15 | 1,400 | $259,000 | $34,210 | 13.2% |
| Q5118 | Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | Office | 2023 | 11 | 1,330 | $210,140 | $33,359 | 15.9% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 14 | 1,560 | $62,400 | $28,734 | 46.0% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 32 | 24,750 | $74,250 | $21,867 | 29.4% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 129 | 141 | $85,023 | $21,486 | 25.3% |
| Q5112 | Injection, trastuzumab-dttb, biosimilar, (ontruzant), 10 mg | Office | 2023 | 15 | 622 | $73,396 | $20,543 | 28.0% |
| Q5116 | Injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg | Office | 2023 | 12 | 909 | $186,345 | $20,425 | 11.0% |
| J3490 | Unclassified drugs | Office | 2023 | 84 | 106 | $58,418 | $18,235 | 31.2% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 252 | 684 | $47,196 | $13,988 | 29.6% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 62 | 10,140 | $50,700 | $13,872 | 27.4% |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2023 | 24 | 2,260 | $63,280 | $13,607 | 21.5% |
| Q5122 | Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | Office | 2023 | 13 | 156 | $131,508 | $13,502 | 10.3% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 386 | 1,216 | $43,776 | $12,445 | 28.4% |
About Dr. Mark Olsen, M.D
Dr. Mark Olsen, M.D is a Hematology & Oncology healthcare provider based in Tulsa, Oklahoma. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1356382592.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Olsen, M.D has received a total of $4,652 in payments from pharmaceutical and medical device companies, with $543.63 received in 2024. These payments were reported across 123 transactions from 44 companies. The most common payment nature is "Food and Beverage" ($2,405).
As a Medicare-enrolled provider, Olsen has provided services to 30,445 Medicare beneficiaries, totaling 691,190 services with total Medicare billing of $9.5M. Data is available for 4 years (2020–2023), covering 374 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Tulsa, OK
- Active Since 06/09/2006
- Last Updated 05/08/2014
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1356382592
Products in Payments
- OPDIVO (Biological) $208.57
- Cabometyx (Drug) $191.99
- Enhertu (Drug) $151.04
- IBRANCE (Drug) $150.18
- Zydelig (Drug) $124.87
- IMBRUVICA (Drug) $105.00
- VARUBI (Drug) $103.15
- Optune (Device) $101.25
- INJECTAFER (Drug) $93.46
- PADCEV (Biological) $90.02
- XPOVIO (Drug) $82.49
- STRATTICE (Device) $76.31
- ADCETRIS (Biological) $66.16
- ZYTIGA (Drug) $63.99
- LIBTAYO (Biological) $59.80
- INQOVI (Drug) $51.16
- Lenvima (Drug) $45.79
- REBLOZYL (Biological) $41.78
- STRATTICE RECONSTRUCTIVE TISSUE MATRIX BPS (Device) $40.41
- BRUKINSA (Drug) $40.39
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Tulsa
Dr. Edwin Mccreary, M.d, M.D
Hematology & Oncology — Payments: $477,532
Hematology & Oncology $477,532
Dr. Ali Moussa, M.d, M.D
Hematology & Oncology — Payments: $11,003
Hematology & Oncology $11,003
Supriya Koya, Md, MD
Hematology & Oncology — Payments: $6,558
Hematology & Oncology $6,558
Dr. Vicki Baker, M.d, M.D
Hematology & Oncology — Payments: $5,946
Hematology & Oncology $5,946
Dr. Jennifer Trottman, Md, MD
Hematology & Oncology — Payments: $4,488
Hematology & Oncology $4,488
Dr. Kevin Weibel, D.o, D.O
Hematology & Oncology — Payments: $4,174
Hematology & Oncology $4,174